What is Protai?
Founded in 2021 and headquartered in Tel Aviv, Israel, Protai is at the forefront of revolutionizing drug discovery. The company utilizes a powerful combination of proteomics and artificial intelligence to delve into new layers of biological understanding. This advanced methodology is designed to accelerate the development of treatments for challenging diseases, positioning Protai as a key player in the health-tech sector.
How much funding has Protai raised?
Protai has raised a total of $20M across 2 funding rounds:
Angel/Seed
$8M
Angel/Seed
$12M
Angel/Seed (2022): $8M with participation from Pitango HealthTech and Grove Ventures Ltd
Angel/Seed (2023): $12M led by Grove Ventures Ltd
Key Investors in Protai
Grove Ventures Ltd
Grove Ventures is a leading early-stage venture capital investment firm with over half-a-billion dollars under management. The company partners early with exceptional Israeli entrepreneurs who believe that the Deep Future is now and are ready to build it.Grove Ventures is headquartered in Tel Aviv-Yafo, Israel.
Pitango HealthTech
Pitango HealthTech is a venture capital firm focused on investing in innovative health technology companies, likely specializing in early to growth-stage opportunities within the Israeli ecosystem.
What's next for Protai?
With its recent major strategic investment and substantial overall backing, Protai is poised for accelerated growth and expanded research and development initiatives. The company's focus on integrating cutting-edge AI with deep biological insights suggests a strategic direction towards enhancing the efficiency and success rates of drug discovery pipelines. This infusion of capital is expected to fuel further innovation, potentially leading to significant advancements in therapeutic development and a stronger market presence.
See full Protai company page
